论文部分内容阅读
目的:研究治疗幽门螺旋杆菌使用左氧氟沙星三联疗法取得的临床效果。方法:选取我院2015年5月-2015年12月收治的200例受到幽门螺旋杆菌感染的患者,随机均分为两组,一组使用左氧氟沙星的三联疗法进行治疗为观察组,一组使用我院标准的三联疗法进行治疗为对照组。两组患者在治疗停药后的一个月后进行呼气试验,检测患者的幽门螺旋杆菌的根除效果,并记录患者在使用期间产生的不良反应。结果:观察组的100例患者中,有92例患者幽门螺旋杆菌得到根除,根除率达到了92%;对照组的100例患者中,有56例患者幽门螺旋杆菌得到根除,根除率达到了56%。两组数据有着明显的差异,p<0.05。观察组中出现不良反应的概率为9%,对照组中出现不良发应的概率为12%,没有统计学的差异。结论:幽门螺旋杆菌患者在临床治疗中,使用左氧氟沙星三联疗法进行治疗,有着很好的根除率,并且产生不良反应的概率和使用标准的三联疗法没有明显的差距,可以在临床中推广使用。
Objective: To study the clinical effect of levofloxacin triple therapy in the treatment of Helicobacter pylori. Methods: A total of 200 patients with Helicobacter pylori infection in our hospital from May 2015 to December 2015 were randomly divided into two groups. One group was treated with levofloxacin triple therapy and the other group was treated with me Hospital standard triple therapy for the control group. The patients in both groups were exhaled one month after treatment was discontinued to detect H. pylori eradication in their patients and their adverse reactions during use were recorded. Results: Of the 100 patients in the observation group, 92 patients had H. pylori eradication and the eradication rate reached 92%. Of the 100 patients in the control group, 56 patients had H. pylori eradication and the eradication rate reached 56 %. There was a clear difference between the two groups, p <0.05. The probability of adverse reactions in the observation group was 9%, and the probability of adverse reactions in the control group was 12%, with no statistical difference. Conclusion: Helicobacter pylori patients in the clinical treatment, the levofloxacin triple therapy for treatment has a good eradication rate, and the probability of adverse reactions and the use of standard triple therapy there is no clear gap can be promoted in the clinical use.